Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38


Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.

Hingorani DV, Doan MK, Camargo MF, Aguilera J, Song SM, Pizzo D, Scanderbeg DJ, Cohen EEW, Lowy AM, Adams SR, Advani SJ.

Mol Cancer Ther. 2020 Jan;19(1):157-167. doi: 10.1158/1535-7163.MCT-18-1302. Epub 2019 Oct 9.


An in vitro study for the dosimetric and radiobiological validation of respiratory gating in conventional and hypofractionated radiotherapy of the lung: effect of dose, dose rate, and breathing pattern.

Cerviño LI, Soultan D, Advani SJ, Cornell M, Yock A, Pettersson N, Song WY, Aguilera J, Murphy J, Hoh C, James C, Paravati A, Coope R, Gill B, Moiseenko V.

Phys Med Biol. 2019 Jul 4;64(13):135009. doi: 10.1088/1361-6560/ab2940.


Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma.

Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA.

Clin Cancer Res. 2017 Oct 1;23(19):5696-5702. doi: 10.1158/1078-0432.CCR-16-3232. Epub 2017 Jul 5.


MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment.

Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani SJ, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh DA, Anand S.

Nat Commun. 2016 Nov 25;7:13597. doi: 10.1038/ncomms13597.


Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.

Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ.

Nat Commun. 2016 Oct 4;7:13019. doi: 10.1038/ncomms13019.


Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer.

Paravati AJ, Hawkins PG, Martin AN, Mansy G, Rahn DA, Advani SJ, Hoisak J, Dragojevic I, Martin PJ, Miller CJ, Sanghvi P.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e659-64. doi: 10.1016/j.prro.2015.07.002. Epub 2015 Jul 17.


Kinase-independent role for CRAF-driving tumour radioresistance via CHK2.

Advani SJ, Camargo MF, Seguin L, Mielgo A, Anand S, Hicks AM, Aguilera J, Franovic A, Weis SM, Cheresh DA.

Nat Commun. 2015 Sep 3;6:8154. doi: 10.1038/ncomms9154.


Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma.

Raju SC, Hauff SJ, Lemieux AJ, Orosco RK, Gross AM, Nguyen LT, Savariar E, Moss W, Whitney M, Cohen EE, Lippman SM, Tsien RY, Ideker T, Advani SJ, Nguyen QT.

Oral Oncol. 2015 May;51(5):470-5. doi: 10.1016/j.oraloncology.2015.01.014. Epub 2015 Feb 27.


Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

Buckel L, Savariar EN, Crisp JL, Jones KA, Hicks AM, Scanderbeg DJ, Nguyen QT, Sicklick JK, Lowy AM, Tsien RY, Advani SJ.

Cancer Res. 2015 Apr 1;75(7):1376-1387. doi: 10.1158/0008-5472.CAN-14-1931. Epub 2015 Feb 13.


Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.

Buckel L, Advani SJ, Frentzen A, Zhang Q, Yu YA, Chen NG, Ehrig K, Stritzker J, Mundt AJ, Szalay AA.

Int J Cancer. 2013 Dec 15;133(12):2989-99. doi: 10.1002/ijc.28296. Epub 2013 Aug 5.


Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.

Advani SJ, Buckel L, Chen NG, Scanderbeg DJ, Geissinger U, Zhang Q, Yu YA, Aguilar RJ, Mundt AJ, Szalay AA.

Clin Cancer Res. 2012 May 1;18(9):2579-90. doi: 10.1158/1078-0432.CCR-11-2394. Epub 2012 Feb 29.


A MEK-independent role for CRAF in mitosis and tumor progression.

Mielgo A, Seguin L, Huang M, Camargo MF, Anand S, Franovic A, Weis SM, Advani SJ, Murphy EA, Cheresh DA.

Nat Med. 2011 Nov 13;17(12):1641-5. doi: 10.1038/nm.2464.


DNA damage response and repair: insights into strategies for radiation sensitization of gliomas.

Kesari S, Advani SJ, Lawson JD, Kahle KT, Ng K, Carter B, Chen CC.

Future Oncol. 2011 Nov;7(11):1335-46. doi: 10.2217/fon.11.111. Review.


Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.

Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR.

Gene Ther. 2011 Nov;18(11):1098-102. doi: 10.1038/gt.2011.61. Epub 2011 May 5.


Enhancing radiotherapy with genetically engineered viruses.

Advani SJ, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2007 Sep 10;25(26):4090-5. Review.


ReVOLT: radiation-enhanced viral oncolytic therapy.

Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR.

Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):637-46. Review.


Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.

Mezhir JJ, Advani SJ, Smith KD, Darga TE, Poon AP, Schmidt H, Posner MC, Roizman B, Weichselbaum RR.

Cancer Res. 2005 Oct 15;65(20):9479-84.


Sustained inhibition of experimental neointimal hyperplasia with a genetically modified herpes simplex virus.

Curi MA, Skelly CL, Meyerson SL, Baldwin ZK, Balasubramanian V, Advani SJ, Glagov S, Roizman B, Weichselbaum RR, Schwartz LB.

J Vasc Surg. 2003 Jun;37(6):1294-300.


Herpes simplex virus 1 activates cdc2 to recruit topoisomerase II alpha for post-DNA synthesis expression of late genes.

Advani SJ, Weichselbaum RR, Roizman B.

Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4825-30. Epub 2003 Mar 28.


Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications.

Advani SJ, Weichselbaum RR, Whitley RJ, Roizman B.

Clin Microbiol Infect. 2002 Sep;8(9):551-63. Review.


The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma.

Chung SM, Advani SJ, Bradley JD, Kataoka Y, Vashistha K, Yan SY, Markert JM, Gillespie GY, Whitley RJ, Roizman B, Weichselbaum RR.

Gene Ther. 2002 Jan;9(1):75-80.


Prevention of restenosis by a herpes simplex virus mutant capable of controlled long-term expression in vascular tissue in vivo.

Skelly CL, Curi MA, Meyerson SL, Woo DH, Hari D, Vosicky JE, Advani SJ, Mauceri HJ, Glagov S, Roizman B, Weichselbaum RR, Schwartz LB.

Gene Ther. 2001 Dec;8(24):1840-6.


Molecular targeting of gene therapy and radiotherapy.

Weichselbaum RR, Kufe DW, Advani SJ, Roizman B.

Acta Oncol. 2001;40(6):735-8. Review.


Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation.

Chmura SJ, Gupta N, Advani SJ, Kufe DW, Weichselbaum RR.

Semin Radiat Oncol. 2001 Oct;11(4):338-45. Review.


Role of cyclin D3 in the biology of herpes simplex virus 1 ICPO.

Van Sant C, Lopez P, Advani SJ, Roizman B.

J Virol. 2001 Feb;75(4):1888-98.


The role of cdc2 in the expression of herpes simplex virus genes.

Advani SJ, Weichselbaum RR, Roizman B.

Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10996-1001.


Strategies for enhancing viral-based gene therapy using ionizing radiation.

Chmura SJ, Advani SJ, Kufe DW, Weichselbaum RR.

Radiat Oncol Investig. 1999;7(5):261-9. Review.


Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.

Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR.

Cancer Res. 1999 May 1;59(9):2055-8.


Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors.

Advani SJ, Chmura SJ, Weichselbaum RR.

Semin Oncol. 1997 Dec;24(6):633-8. Review.


Supplemental Content

Loading ...
Support Center